Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Thailand insole OEM manufacturer

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Latex pillow OEM production in Taiwan

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Memory foam pillow OEM factory Indonesia

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Smart pillow ODM manufacturer Thailand

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Memory foam pillow OEM factory Taiwan

Like a bonsai, neurons called mitral cells also grow multiple branches. In the beginning, mitral cells branch into many glomeruli, but as development progresses, a single branch is strengthened and the others are pruned away. Kyushu University researchers studying mouse olfactory neurons found that BMPR-2 is one of the key regulators of selective stabilization of neuron branching and that strengthening of that input only happens in the presence of neuron signaling. Credit: Kyushu University, bonsai provided by @h.h.rockkraft on Instagram Researchers identify molecular cues that make developing neurons remodel their connections. At this very moment, the billions of neurons in your brain are using their trillions of connections to enable you to read and comprehend this sentence. Now, by studying the neurons involved in the sense of smell, researchers from Kyushu University’s Faculty of Medical Sciences report a new mechanism behind the biomolecular bonsai that selectively strengthens these connections. How neuronal circuits remodel themselves over time, especially during early development, is an open question in neurobiology. At the start of neuronal development, neurons form excessive amounts of connections that are gradually eliminated as others are strengthened. Studying a type of olfactory neuron known as a mitral cell in mice, the research team found that the protein BMPR-2 is one of the key regulators of selective stabilization of neuron branching and that the strengthening only happens when the branch receives signals from other neurons. “A main reason we use olfactory neurons is because they are easy to access and study, and mitral cells develop only a single branch,” explains Shuhei Aihara, first author of the study published in Cell Reports. At an early stage of mouse development, the mitral cells connect to multiple glomeruli. As development progresses, excess branches are pruned away, and eventually each mitral cell establishes a single branch to only one glomerulus innervating for a single odor. Credit: Kyushu University/Imai Lab “When an olfactory neuron detects a specific molecule that we smell, it sends the signal to a specific ‘way station’ in the brain’s olfactory bulb called a glomerulus. That signal is then relayed to the brain through mitral cells. One mitral cell receives signals for one specific smell.” At a very early stage in development, these mitral cells send branches into many glomeruli. As time progresses, these branches—known as dendrites—are pruned away to leave only a single, strong connection. The research team set out to uncover what kind of molecular cues caused one branch to be favored over others. After analyzing candidate factors known to control dendritic growth and remodeling from extrinsic signals, the team focused on the protein BMPR-2. “When we disrupted BMPR-2, mitral cells would fail in the selective stabilization and form multiple connections to multiple glomeruli,” explains Aihara. “In our next step, we found that BMPR-2 is bound to a protein called LIMK, and only when BMPR-2 is activated by the cell-signaling protein called BMP does it release LIMK into the cell.” LIMK is known to activate the process to assemble actin, the cell’s ‘skeleton.’ Once activated, actin begins to build long fibers that stabilize dendrites. However, this still did not explain how this mechanism strengthens specific dendrites. The team’s next step was to find the elements that activate LIMK. Their investigation led them to identify a well-known neurotransmitter, glutamic acid, as one of the factors that kicks off the process. “Glutamic acid is required for signals to be transmitted between neurons. Taken together, this means that both BMP and neural signals are necessary to form actin, thereby inducing the construction of a stable dendrite,” states Aihara. “It’s like the brake and accelerator in your car. You need to release the brake, in this case BMPR-2 releasing LIMK, and then press on the accelerator—the neurotransmitter signal—for your machinery to move forward. The necessity of simultaneous control, or inputs, is the basis of selective branch stabilization.” Takeshi Imai, who led the team, concludes, “Hopefully these new insights into neural development can lead to further understanding of the fundamental mechanisms behind critical brain functions and possible treatments into pathologies underlined by synaptic dysfunction.” “Our next step is to find the factors that promote dendrite pruning, and we also want to see if this mechanism in the olfactory bulb is fundamental throughout the neocortex.” Reference: “BMPR-2 gates activity-dependent stabilization of primary dendrites during mitral cell remodeling” by Shuhei Aihara, Satoshi Fujimoto, Richi Sakaguchi and Takeshi Imai, 22 June 2021, Cell Reports. DOI: 10.1016/j.celrep.2021.109276

A new study from the Netherlands Institute for Neuroscience addresses the longstanding controversy over the brain’s regenerative abilities and proposes a roadmap for resolving conflicting results. Researchers critically discussed and re-analyzed previously published datasets, highlighting the importance of accurate reporting and reproducibility in single-cell transcriptomics experiments to uncover the true potential of brain regeneration. Recent research highlights the rarity of neurogenesis in humans and the need for species-specific markers, paving the way for innovative treatments for brain disorders. Can the human brain regenerate itself? And is it possible to harness this regenerative capacity during aging or in neurodegenerative conditions? These questions have long been the subject of intense debate within the neuroscience community. A recent study from the Netherlands Institute for Neuroscience sheds light on why conflicting results have emerged and suggests a path forward for addressing these challenges. Leveraging the brain’s regenerative potential in the context of aging or neurological disorders offers a promising alternative to traditional approaches for enhancing or restoring brain function, particularly given the current absence of effective treatments for neurodegenerative diseases like Alzheimer’s. The debate over whether the human brain can indeed regenerate has been a contentious issue for many years, with recent studies producing contradictory findings. In a new study, Giorgia Tosoni and Dilara Ayyildiz, working under the guidance of Evgenia Salta at the Neurogenesis and Neurodegeneration Laboratory, critically assess and re-evaluate previously published data. This study aims to clarify the reasons behind the lack of a definitive answer to this intriguing question. Previous studies in which dividing cells were labeled in the postmortem human brain, showed that new cells can indeed arise throughout adulthood in the hippocampus of our brain, a structure that plays an important role in learning and memory, and is also severely affected in Alzheimer’s disease. However, other studies contradict these results and cannot detect the generation of new brain cells in this area. Both conceptual and methodological confounders have likely contributed to these seemingly opposing observations. Hence, elucidating the extent of regeneration in the human brain remains a challenge. Difficulties in detecting hippocampal regeneration. Credit: Netherlands Institute for Neuroscience New State-of-the-Art Technologies Recent advances in single-cell transcriptomics technologies have provided valuable insights into the different cell types found in human brains from deceased donors with different brain diseases. To date, single-cell transcriptomic technologies have been used to characterize rare cell populations in the human brain. In addition to identifying specific cell types, single-nucleus RNA sequencing can also explore specific gene expression profiles to unravel full the complexity of the cells in the hippocampus. The advent of single-cell transcriptomics technologies was initially viewed as a panacea to resolving the controversy in the field. However, recent single-cell RNA sequencing studies in the human hippocampus yielded conflicting results. Two studies indeed identified neural stem cells, while a third study failed to detect any neurogenic populations. Are these novel approaches – once again – failing to finally settle the controversy regarding the existence of hippocampal regeneration in humans? Will we eventually be able to overcome the conceptual and technical challenges and reconcile these -seemingly- opposing views and findings? Technical Issues In this study, the researchers critically discussed and re-analyzed previously published single-cell transcriptomics datasets. They caution that the design, analysis, and interpretation of these studies in the adult human hippocampus can be confounded by specific issues, which ask for conceptual, methodological, and computational adjustments. By re-analyzing previously published datasets, a series of specific challenges were probed that require particular attention and would greatly profit from an open discussion in the field. Giorgia Tosoni: ‘We analyzed previously published single-cell transcriptomic studies and performed a meta-analysis to assess whether adult neurogenic populations can reliably be identified across different species, especially when comparing mice and humans. The neurogenic process in adult mice is very well characterized and the profiles of the different cellular populations involved are known. These are actually the same molecular and cellular signatures that have been widely used in the field to also identify neurogenic cells in the human brain. However, due to several evolutionary adaptations, we would expect the neurogenesis between mice and humans to be different. We checked the markers for every neurogenic cell type and looked at the amount of marker overlap between the two species.’ ‘We found very little, if no, overlap between the two, which suggests that the mouse-inferred markers we have been long using may not be suitable for the human brain. We also discovered that such studies require enough statistical power: if regeneration of neuronal cells does happen in the adult human brain, we expect it to be quite rare. Therefore, enough cells would need to be sequenced in order to identify those scarce, presumably neurogenic populations. Other parameters are also important, for example, the quality of the samples. The interval between the death of the donor and the downstream processing is critical, since the quality of the tissue and of the resulting data drops over time.’ Reproducibility Is Key Dilara Ayyildiz: “These novel technologies, when appropriately applied, offer a unique opportunity to map hippocampal regeneration in the human brain and explore which cell types and states may be possibly most amenable to therapeutic interventions in aging, neurodegenerative and neuropsychiatric diseases. However, reproducibility and consistency are key. While doing the analysis we realized that some seemingly small, but otherwise very critical details and parameters in the experimental and computational pipeline, can have a big impact on the results, and hence affect the interpretation of the data.” “Accurate reporting is essential for making these single-cell transcriptomics experiments and their analysis reproducible. Once we re-analyzed these previous studies applying common computational pipelines and criteria, we realized that the apparent controversy in the field may, in reality, be misleading: with our work, we propose that there may actually be more that we agree on than previously believed.” Reference: “Mapping human adult hippocampal neurogenesis with single-cell transcriptomics: Reconciling controversy or fueling the debate?” by Giorgia Tosoni, Dilara Ayyildiz, Julien Bryois, Will Macnair, Carlos P. Fitzsimons, Paul J. Lucassen and Evgenia Salta, 3 April 2023, Neuron. DOI: 10.1016/j.neuron.2023.03.010

Researchers have successfully engineered a type of skin bacterium to treat acne by producing a therapeutic molecule. This innovative approach, validated in lab and mouse models, could revolutionize the treatment of skin conditions and other diseases using living therapeutics. A breakthrough study shows that engineered skin bacteria can effectively treat acne, opening new possibilities for living therapeutics in various diseases. International research led by the Translational Synthetic Biology Laboratory of the Department of Medicine and Life Sciences (MELIS) at Pompeu Fabra University has succeeded in efficiently engineering Cutibacterium acnes — a type of skin bacterium — to produce and secrete a therapeutic molecule suitable for treating acne symptoms. The engineered bacterium has been validated in skin cell lines and its delivery has been validated in mice. This finding opens the door to broadening the way for engineering non-tractable bacteria to address skin alterations and other diseases using living therapeutics. The research team is completed by scientists from the Bellvitge Biomedical Research Institute (Idibell), the University of Barcelona, the Protein Technologies Facility of the Centre for Genomic Regulation, Phenocell SAS, Medizinische Hochschule Brandenburg Theodor Fontane, Lund University, and Aarhus University. Understanding Acne and Its Traditional Treatments Acne is a common skin condition caused by the blockage or inflammation of the pilosebaceous follicles. Its appearance can vary, ranging from whiteheads and blackheads to pustules and nodules, mainly on the face, forehead, chest, upper back, and shoulders. Although acne is most common among adolescents, it can affect people of all ages. The most severe cases of acne are treated with antibiotics to kill bacteria living in the follicles, or isotretinoin (known as Accutane), a vitamin A derivative, which induces the death of sebocytes, the epithelial skin cells that produce sebum. However, these treatments can cause serious side effects such as breaking skin microbiome homeostasis -because they are not selectively killing bacteria- or photosensitivity, in the case of antibiotics, or birth defects or extreme scaling of skin, in the case of isotretinoin. A Breakthrough in Acne Treatment The results of the study, published today (January 9) in Nature Biotechnology, show that researchers have successfully edited the genome of Cutibacterium acnes to secrete and produce NGAL protein known to be a mediator of the acne drug, isotretinoin, which has been shown to reduce sebum by inducing the death of sebocytes. “We have developed a topical therapy with a targeted approach, using what nature already has. We engineered a bacterium that lives in the skin and make it produce what our skin needs. Here, we focused on treating acne, but this platform can be extended to several other indications,” says Nastassia Knödlseder, first author of the study. Challenges and Advances in Bacterial Engineering “Until now, C. acnes was considered an intractable bacterium. It was incredibly difficult to introduce DNA and get proteins produced or secreted from an element inserted into its genome,” explains Knödlseder, who is a postdoc in the UPF Translational Synthetic Biology Laboratory. However, since C. acnes seems an attractive synthetic biology chassis for treating skin diseases due to its niche environment deep inside hair follicles -practically where sebum is released-, its importance for skin homeostasis, its close contact to relevant therapeutic targets, plus the fact that it has been shown to successfully engraft when applied to human skin, led them to insist on editing the genome of this non-engineerable bacterium. To edit the genome of C. acnes, the research team led by Marc Güell has focused on improving DNA delivery to the cell, DNA stability inside the cell, and gene expression. The scientists have considered regulatory measures by developing a biocontainment strategy to avoid the use of elements that generate regulatory concerns such as mobile genetic elements, plasmids or antibiotic resistance. Hence, the resulting synthetic bacterium has safety features to enable “real-life application” and consider it for future human therapeutics. Synthetic C. acnes is able to secrete and produce NGAL to modulate sebum production in cell lines. When applied to the skin of mice — the only animal model able to test engineered bacteria to date — they engraft, live, and produce the protein. However, mice’s skin is not comparable to humans’. It has more hair, is looser, has less lipids, and a different sweat mechanism. Hence the need for an alternative model, better representing human skin, such as 3D skin models. Expanding the Scope of Therapeutics “We have developed a technology platform that opens the door to editing any bacteria to treat multiple diseases. We are now focused in using C. acnes to treat acne but we can deliver genetic circuits to create smart microbes for applications related to skin sensing, or immune modulation,” points out Marc Güell, who has led the research. Following the same strategy, this research line will continue under the European Project ‘SkinDev’ in which scientists from the Translational Synthetic Biology lab together with its partners will engineer C. acnes to address atopic dermatitis, a chronic cutaneous inflammatory condition characterized by dry skin, eczema, and severe irritation, especially common among young children. Although any living therapeutics strategy should be validated individually, the researchers show their optimism in applying these smart microbes to humans because non-engineered C. acnes has already been tested on the skin of patients safely and effectively. Reference: “Delivery of a sebum modulator by an engineered skin microbe in mice” by Nastassia Knödlseder, María-José Fábrega, Javier Santos-Moreno, Joan Manils, Lorena Toloza, Maria Marín Vilar, Cristina Fernández, Katrina Broadbent, Julien Maruotti, Hélène Lemenager, Carlo Carolis, Christos C. Zouboulis, Concepció Soler, Rolf Lood, Holger Brüggemann and Marc Güell, 9 January 2024, Nature Biotechnology. DOI: 10.1038/s41587-023-02072-4

DVDV1551RTWW78V